Henry Schein (NASDAQ:HSIC) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

02 Jul 2026, 23:40 by Tristan Rich · The Markets Daily

Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $76.87 and traded as high as $84.42. Henry Schein shares last traded at $83.52, with a volume of 1,250,689 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Robert W. Baird set a $97.00 target price on shares of Henry Schein in a research note on Wednesday, May 6th. Mizuho cut their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Finally, BTIG Research upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Thursday, June 11th. Seven equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $87.85.

View Our Latest Stock Report on Henry Schein

Henry Schein Stock Up 2.3%

The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36. The stock’s fifty day simple moving average is $76.88 and its two-hundred day simple moving average is $76.93. The stock has a market capitalization of $9.85 billion, a P/E ratio of 26.11, a price-to-earnings-growth ratio of 1.61 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm had revenue of $3.37 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the company posted $1.15 EPS. The business’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, research analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Insider Buying and Selling

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of Henry Schein stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, with a total value of $691,900.00. Following the transaction, the director owned 20,000 shares in the company, valued at $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.89% of the company’s stock.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently made changes to their positions in the business. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the 2nd quarter valued at $27,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Henry Schein during the fourth quarter worth $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein in the fourth quarter worth $32,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Henry Schein in the fourth quarter worth $37,000. 96.62% of the stock is currently owned by institutional investors.

About Henry Schein

(Get Free Report)

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.